

**REMARKS**

The specification has been amended to provide a cross-reference to prior co-pending application Serial No. 09/913,106.

Prior to this amendment, Claims 1-27 were in the application.

Claims 1-3, 5, 8, 9, 11, 16, 22 and 23 have been amended to put them in appropriate U.S. claim format, eliminate multiple dependencies and delete therefrom subject matter elected for prosecution in parent application Serial No. 09/913,106.

Claims 6, 7, 10, and 12-15 have been cancelled, the subject matter thereof having been elected for prosecution in the parent application.

Claim 4 has been cancelled as redundant in view of the amendment of Claim 1 limiting X to the group  $R_2-N$ .

Claims 17-21 have been cancelled and rewritten in independent form as new claims 30-34.

Claims 25-27 have been cancelled and replaced by new independent Claim 35 and Claims 36-39 written in singly dependent form.

New Claims 28 and 29 correspond to original claims 11 and 23 written as singly dependent from Claim 9.

No new matter is added by these amendments.

Claims 1-3, 5, 8, 9, 11, 16, 22, 23, and 28-39 are in the application as presently amended.

Respectfully submitted,

Date:

9/16/03

  
PAUL E. DUPONT  
Reg. No. 27,438

Address  
Patent Department  
Sanofi-Synthelabo Inc.  
9 Great Valley Parkway  
Malvern, PA 19355  
Telephone No. (610) 889-6338  
Facsimile: (610) 889-8799